Date:2/24/2010

CARLSBAD, Calif., Feb. 24 /PRNewswire/ -- AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.

The featured four-part series in The New York Times, this week focuses on the importance of B-RAF mutations and the next generation of cancer therapies. "We congratulate Plexxikon and Roche on the dramatic success of their compound PLX-4032, a novel treatment for melanoma and other cancers harboring the V600E mutation of the B-RAF kinase gene," said Robert Cole, M.D., Chief Medical Officer at AutoGenomics.

Melanoma is the most serious type of skin cancer with about 70,000 new melanoma cases diagnosed every year in the USA and about 160,000 worldwide. Whe
'/>"/>

SOURCE AutoGenomics Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. AutoGenomics Receives ISO Certification
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. FDA Announces Possible Safety Concern for HIV Drug Combination
5. Microfluidics International Corporation Announces Fourth Quarter and Year-End 2009 Financial Results
6. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Its Second Quarter of Fiscal Year 2010
7. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
8. Ethicon Endo-Surgery Announces Agreement with Hologic Inc. To Resolve Patent Disputes
9. Pioneer(R) Surgical Technology, Inc. Announces New CTO
10. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
11. Echo Therapeutics Announces Significant Product Development Milestone: The Completion of Next Generation Electronic Components for Its Revolutionary, Patented Symphony(TM) tCGM System